65,437 trials
GVHD · Hematologic Neoplasms
Primary: Occurrence of Moderate and Severe Chronic GVHD at One Year Post Transplant — 0; 8 Participants
Atopic Dermatitis · Plaque Psoriasis
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=)…
Cryptosporidium Infection, Cryptosporidiosis
Primary: Percentage of Participants With Cryptosporidium Infection From 72 Hours to 10 Days Post ABO809 Oral Administration — 50; 57.1; 60.0 percentage of participants
Stroke, Acute
Primary: Ischemic Stroke Diagnostic Accuracy (CBCT Versus CT) — 90; 90 percentage of gold standard
Anxiety, Dental · Dental Decay
Primary: Incidence of Adverse Sedation-Related Events in Musculoskeletal System During Sedation — 2.8; 3; 2.5500 score on a scale — p=0.016
Schizophrenia
Primary: Part 1 & 2: Number of Participants Who Experienced an Adverse Event (AE) — 4; 9; 3; 2 Participants
Tuberculosis, Meningeal
Primary: Drug Clearance (CL/F) — 6.24 L/hr
Biological Availability
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant — 83.65; 102.5; 184.4; 47.29 Hours*nanograms per milliliter (h*ng/mL)
Type 1 Diabetes Mellitus
Primary: Percent Time Spent Between 70 and 180 mg/dL — 66.4; 53.9; 59.9; 57.7 percentage of time — p=0.010
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
Plaque Psoriasis
Primary: Number of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52. — 70; 32 Participants — p=<0.0001
Acute Respiratory Distress Syndrome · ARDS (Moderate or Severe) · COVID-19 Pneumonia
Primary: Incidence of Grade 3-5 Infusional Toxicities and Predefined Hemodynamic or Respiratory Adverse Events Related to the Infusion of MSC — 0; 0 Participants
Diabetes Mellitus, Type 2
Primary: Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1 — 287.4 nanogram*hour per milliter (ng*hr/mL)
Acne Vulgaris
Primary: Comparison of the Change From Baseline of Count Lesions on Each Visit to Evaluate the Efficacy and Clinical Performance of Crystal Peel for the Treatment of Acne. — 943…
Bullying
Primary: Knowledge and Confidence to Support Defenders — 30.71; 37.34 score on a scale